🔗 Share this article

As the United States undertakes historic revisions to its immunization recommendations, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by expressing skepticism about Covid shots throughout the pandemic and has zeroed in on potential deaths after COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Program

Health officials planned to announce sweeping changes to the childhood immunization program earlier this month, bringing the US with Denmark’s national calendar, according to reports – a major change that would place the US out of alignment with much of the global community with little proof for improved outcomes. The planned update has been delayed until the coming year.

Instead of Vinay Prasad, Dr. Høeg is listed to speak at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to run the office this year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a tighter collaboration between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a renewed priority upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for halting specific pediatric vaccine recommendations in the US in order to be more similar to Denmark, a society with nationalized medicine and a population approximately the size of the state of Wisconsin.

To date public appearances, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Questions Over Expertise

Dr. Høeg has no apparent background in pharmaceutical research, oversight or administrative roles, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and CBER since spring.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in running a large organization. She lacks background in pharmaceutical oversight.”

Former heads of the center would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she lacks the type of experience that prior appointees who led CBER have had.”

CDER has an enormous workload at the agency, she pointed out.

“Everybody just pays attention on the novel medication approvals, but the generic program authorizes a multitude of generic drugs. There is also a biosimilars division, OTC medication office and more, and each of these have to be supervised,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

There is also, a major administrative component to the job, which supervises over 5,000 personnel. “It’s a huge administrative position, if you do it right,” Woodcock added.

Official Statement and Controversial Initiatives

In response to inquiries about Høeg’s fitness for the role and whether this assignment indicates increased cooperation among regulatory chiefs on immunizations, a representative said that the “questions stem from flawed premises”.

“Her experience matches the functions of her role,” the spokesperson explained, pointing to the period Dr. Høeg spent advising the agency head on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a contentious rapid drug-approval program that allegedly concerned her preceding directors. “By what process are these drugs being chosen for this voucher program? Who takes the decisions?” Howard asked. “There is a lot of confidentiality happening at the FDA right now.”

In general, he said, “the Food and Drug Administration seems to be moving towards less stringent oversight of all drugs, with the exception of vaccines.”

Established Past Work on Vaccines

Concerning vaccines, Høeg has a more documented, if concerning, track record, some experts observe. She authored a analysis using unconfirmed public submissions to assess the incidence of heart inflammation following Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the new federal leadership encompassed changing rules for new vaccines and halting “non-essential” vaccines, she stated post-election on a audio program. At the FDA, Høeg has reportedly floated the idea of excluding teenage boys from receiving Covid vaccines.

“She’s an complete ideologue who starts off with her preconceived notions and works backwards to fit the data in a very deceptive, fraudulent way,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Høeg joined fellow skeptics, {like|